FDA Accepts Sandoz Two Abbreviated New Drug Applications for Generic Tirzepatide Autoinjectors (Generic Mounjaro and Zepbound) on Monday June 29: Sandoz Positions to Launch 'One of the First Generic Tirzepatide Products' in the US Once Approvals Land, Adding Supply-Side Variable to Medicare Bridge Economics
Sandoz Group announced Monday June 29, 2026 that the FDA accepted two Abbreviated New Drug Applications (ANDAs) from the company for generic versions of Eli Lilly's tirzepatide autoinjectors, covering the type-2-diabetes-labeled Mounjaro and the obesity-labeled Zepbound. The ANDAs cover all approved indications of Mounjaro and Zepbound. If approvals land, Sandoz would launch 'one of the first generic tirzepatide products' in the US, adding real supply-side competition to Lilly's branded product and creating pricing pressure that could reshape the Medicare GLP-1 Bridge economics. The company developed the generic tirzepatide in-house, combining Sandoz's small-molecule and device-development experience with its biosimilar expertise. The ANDA acceptance does not include a projected FDA action date; typical generic-tirzepatide review timelines run 12 to 24 months, putting a potential Sandoz launch window in 2027-2028. The competitive-pressure question is whether generic tirzepatide substitution would apply at the pharmacy counter under the Bridge (the program covers Zepbound KwikPen brand-specifically) or only in the broader Part D market post-Bridge.